Alligator Bioscience AB (0RK9)

Profile

https://www.alligatorbioscience.se

Alligator Bioscience AB is a clinical-stage biotechnology company focused on developing tumor-directed immuno-oncology antibody drugs, particularly those targeting the CD40 receptor pathway. Its primary purpose is to activate the patient's immune system directly within the tumor microenvironment, overcoming immune suppression to elicit potent anti-tumor responses. The company's lead asset, mitazalimab, a CD40 agonist, is advancing toward Phase 3 development in first-line metastatic pancreatic cancer after promising Phase 2 OPTIMIZE-1 trial results, including unprecedented 24-month survival outcomes in this challenging indication. Alligator Bioscience AB maintains a robust pipeline of mono- and bispecific antibody programs designed for localized immune activation, balancing efficacy and safety. Founded in 2001 and headquartered at Medicon Village in Lund, Sweden, the company plays a significant role in advancing immunotherapies for hard-to-treat cancers, contributing to innovation in the biotechnology sector.